As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population. Read more
Runner and patient advocate Angus Pratt says running three times a week may be the antithesis of what most people expect from a lung cancer patient, but not only is it possible, it is beneficial. Read more
With only 5% of patients stopping treatment due to treatment-related adverse events, lead author Yuankai Shi, MD, says glecirasib may help improve patient compliance with oral therapy. Read more
The first-in-class immunotherapy offers a new option for SCLC patients with disease progression on or after platinum-based chemotherapy. Read more
In a two-part commentary, Dr. Ke-Neng Chen discusses how surgeons must adjust in light of recent clinical trials, beginning with a discussion of the challenges of TNM staging. Read more
As thoracic surgery in the management of NSCLC evolves, Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach. Read more
In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions. Read more
In other regulatory news, the US FDA recently granted a Breakthrough Therapy Designation for sunvozertinib for first-line treatment of advanced non-small cell lung cancer with EGFR Exon 20 Insertion mutations. Read more
Submit abstracts for ACLC 2024 by June 7, register for the 2024 CT Screening Symposium, and contribute memories for the 50th anniversary time capsule. Read more
Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed. Read more